Natco, INE987B01026

Natco Pharma stock: Q2 net profit falls 61% to INR 203 crore

Published on 11/20/2026 at 03:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Natco Pharma stock will pay a second interim dividend of INR 1.25 per share. The record date was November 19, with payment starting November 27.

Results show a sharp earnings decline

  • Revenue from operations fell 29 percent year over year in the September quarter.
  • The board approved a second interim dividend, with payment scheduled to begin on November 27.
  • Lower Lenalidomide revenue weighed on the quarter, while international formulations remained the largest revenue contributor.
Natco, INE987B01026, Illustration mit AI erstellt.

Natco Pharma reported its September-quarter results for FY27 on Friday, November 13, 2026. According to Business Today, consolidated profit after tax fell to INR 202.6 crore from INR 517.9 crore a year earlier. Consolidated total revenue declined to INR 1,019.4 crore from INR 1,463 crore.

Quarterly results point to weaker earnings

Revenue from operations fell 29 percent year over year to INR 967.3 crore. EBITDA before the share of profit from the associate stood at INR 310 crore, compared with INR 679.2 crore in the corresponding quarter last year.

Natco said lower Lenalidomide revenue drove much of the decline, partly offset by growth in its base business and subsidiaries. International formulations contributed INR 668.4 crore, while domestic pharmaceutical formulations generated INR 145.7 crore and active pharmaceutical ingredients contributed INR 61.3 crore.

Dividend sets a near-term shareholder date

The board declared a second interim dividend of INR 1.25 per equity share with a face value of INR 2 for FY27. November 19, 2026 was set as the record date, and payment is scheduled to begin on November 27, 2026.

Natco also increased its holding in South African associate Adcock Ingram Holdings to 49 percent by acquiring an additional 13.25 percent stake during the quarter. The associate contributed INR 29.2 crore to Natco's profit after adjustments related to the provisional purchase price allocation.

Natco's generic-drug operations

Natco Pharma develops, manufactures and markets finished dosage formulations, active pharmaceutical ingredients and intermediates. Its portfolio includes oncology, central nervous system, pain management, cardiovascular and gastrointestinal products, along with crop-health solutions.

Headquartered in Hyderabad, India, the company sells products in more than 50 countries, including the United States, India, Canada and Brazil. Its focus on complex and specialty generics gives it a more specialized profile than broad-based pharmaceutical manufacturers, while its international footprint complements its Indian business.

Natco operates in the Indian market environment covered by the BSE Sensex.

More news and analyses on Natco Pharma stock are available here.

Natco Pharma at a glance

  • Company: Natco Pharma Limited
  • ISIN: INE987B01026
  • Ticker: NATCOPHARM.NS
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Specialty & Generic
  • Headquarters: Hyderabad, India
  • Q2 FY27 reporting period: Quarter ended September 30, 2026
  • Second interim dividend: INR 1.25 per share
Disclaimer...
en | INE987B01026 | NATCO | boerse | 70538335 | bgmi